Compare MREO & ASA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | MREO | ASA |
|---|---|---|
| Founded | 2015 | 1958 |
| Country | United Kingdom | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Precious Metals |
| Sector | Health Care | Industrials |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 52.5M | 1.3B |
| IPO Year | 2017 | 2003 |
| Metric | MREO | ASA |
|---|---|---|
| Price | $0.23 | $61.59 |
| Analyst Decision | Buy | |
| Analyst Count | 5 | 0 |
| Target Price | ★ $1.50 | N/A |
| AVG Volume (30 Days) | ★ 1.5M | 57.5K |
| Earning Date | 05-11-2026 | 06-01-2026 |
| Dividend Yield | N/A | ★ 0.10% |
| EPS Growth | ★ 16.67 | N/A |
| EPS | N/A | ★ N/A |
| Revenue | ★ $500,000.00 | N/A |
| Revenue This Year | $5,184.20 | N/A |
| Revenue Next Year | $55.51 | N/A |
| P/E Ratio | ★ N/A | $1.96 |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $0.20 | $29.72 |
| 52 Week High | $2.94 | $83.20 |
| Indicator | MREO | ASA |
|---|---|---|
| Relative Strength Index (RSI) | 31.79 | 38.25 |
| Support Level | $0.21 | $55.79 |
| Resistance Level | $0.36 | $63.02 |
| Average True Range (ATR) | 0.03 | 2.74 |
| MACD | 0.00 | -0.47 |
| Stochastic Oscillator | 16.67 | 3.32 |
Mereo BioPharma Group PLC is a United Kingdom (U.K.) based biopharmaceutical company focused on the development of therapeutics for rare diseases. The company has developed a portfolio of late-stage clinical product candidates, and its two rare disease product candidates are setrusumab for the treatment of osteogenesis imperfecta (OI) and alvelestat, mainly for the treatment of severe alpha-1 antitrypsin deficiency-associated lung disease (AATD-LD).
ASA Gold And Precious Metals Ltd is a closed-end, non-diversified investment company. Its objective is to provide long-term capital appreciation through investing in companies engaged in the exploration for, development of projects, or mining of precious metals and minerals.